Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Cough - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Chronic Cough - Pipeline Review, H2 2016', provides an overview of the Chronic Cough pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Cough and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Cough - The report reviews pipeline therapeutics for Chronic Cough by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Chronic Cough therapeutics and enlists all their major and minor projects - The report assesses Chronic Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Chronic Cough Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chronic Cough - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chronic Cough pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Chronic Cough Overview 7 Therapeutics Development 8 Pipeline Products for Chronic Cough - Overview 8 Pipeline Products for Chronic Cough - Comparative Analysis 9 Chronic Cough - Therapeutics under Development by Companies 10 Chronic Cough - Therapeutics under Investigation by Universities/Institutes 11 Chronic Cough - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Chronic Cough - Products under Development by Companies 14 Chronic Cough - Products under Investigation by Universities/Institutes 15 Chronic Cough - Companies Involved in Therapeutics Development 16 Afferent Pharmaceuticals, Inc. 16 AstraZeneca Plc 17 Conrig Pharma ApS 18 GlaxoSmithKline Plc 19 Glenmark Pharmaceuticals Ltd. 20 GW Pharmaceuticals Plc 21 NeRRe Therapeutics Ltd 22 Patara Pharma, Inc. 23 Pila Pharma AB 24 Chronic Cough - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 33 AF-219 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 cromolyn sodium - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 GRC-17536 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 GSK-2339345 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 lesogaberan - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 NEO-5937 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 orvepitant maleate - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 S-1226 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 ST-015 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 XEND-0501 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Chronic Cough - Dormant Projects 51 Chronic Cough - Discontinued Products 52 Chronic Cough - Product Development Milestones 53 Featured News & Press Releases 53 Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis 53 May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference 54 May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors 56 Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial 56 Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 57 Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company's Lead P2X3 Antagonist, AF-219 58 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 60 Disclaimer 61
List of Tables
Number of Products under Development for Chronic Cough, H2 2016 8 Number of Products under Development for Chronic Cough - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Chronic Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 16 Chronic Cough - Pipeline by AstraZeneca Plc, H2 2016 17 Chronic Cough - Pipeline by Conrig Pharma ApS, H2 2016 18 Chronic Cough - Pipeline by GlaxoSmithKline Plc, H2 2016 19 Chronic Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 20 Chronic Cough - Pipeline by GW Pharmaceuticals Plc, H2 2016 21 Chronic Cough - Pipeline by NeRRe Therapeutics Ltd, H2 2016 22 Chronic Cough - Pipeline by Patara Pharma, Inc., H2 2016 23 Chronic Cough - Pipeline by Pila Pharma AB, H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Number of Products by Stage and Target, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 31 Number of Products by Stage and Molecule Type, H2 2016 32 Chronic Cough - Dormant Projects, H2 2016 51 Chronic Cough - Discontinued Products, H2 2016 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
